Specials

Biotech-310x175_copy

What were the top 20 M&A deals in pharma and biotech sector in 2012?...

  • China
  • |
  • Analysis

A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek out partners for mergers & acquisition (M&A). Also read: • Why did mergers... Read more

biospectrum-asia-top-20-survey-rank-1-sinopharm-group-china

Sinopharm demonstrates king size growth, yet again...


  • China
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

Sinopharm, a dominant name in the distribution of pharmaceutical and healthcare products in China, continues to grab a large... Read more

Biotech-310x175_copy

Australia is 3rd largest in terms of total company...


  • Australia
  • |
  • Analysis
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Australia emerged as the third largest country in terms of the total revenue generated by companies during the calendar year... Read more

11b-biospectrum-asia-top-20-survey-rank-11-lupin-india

Lupin gets 16 FDA nods, launches 11 products front

  • India
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

US remained an unstirred focus for Indian pharmaceutical company Lupin as it went on achieving 16 approvals from US FDA and launched 11... Read more

10b-biospectrum-asia-top-20-survey-rank-10-resmed-australia

Resmed dominates the niche sleep disorder market

  • Australia
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

A distinguished name in treating, diagnosing and managing sleep-disordered breathing (SDB) and other respiratory disorders, ResMed continues... Read more

9b-biospectrum-asia-top-20-survey-rank-9-dr

Dr. Reddy’s makes a mark in the US generics market

  • India
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

Striking profit on a high note, Dr. Reddy's crossed $1.5 billion worth of business in 2012, marking a growth of 22 percent. Dr. Reddy's... Read more

8b-biospectrum-asia-top-20-survey-rank-8-cipla-india

Cipla keeps the flag high for affordable drugs

  • India
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

Cipla, which is known for providing affordable drugs to cancer and HIV patients in developing countries, clocked a growth of 17 percent... Read more

7b-biospectrum-asia-top-20-survey-rank-7-north-china-pharma-china

North China Pharma integrates R&D strength in its system

North China Pharmaceutical Company (NCPC) faced a decline of around 26 percent in 2012. The company is principally engaged in the production... Read more

6b-biospectrum-asia-top-20-survey-rank-6-yunnan-baiyao-china-profile

TCM leader Yunnan Baiyao rides on R&D strength

Yunnan Baiyao Group is expanding its forte in the domain of traditional Chinese medicines and is concentrating on strengthening its R&D... Read more

5b

Ranbaxy retains grip on generics market

Ranbaxy became the first Indian firm to develop a new drug called Synriam for malaria, which is a health menace that claims half a million... Read more

biospectrum-asia-top-20-survey-rank-4-china-national-accord-medicines-china

China National Accord’s R&D strategy begins to pay-off

  • China
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

China National Accord Medicines Corporation utilized 2012 as a year to speed up the transformation and upgrade scientific development by... Read more

biospectrum-asia-top-20-survey-rank-3-sigma-pharmaceutical-australia

Sigma Pharma leverages on its pharmacy business

  • Australia
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

Marking a strong presence of 100 years in the pharmaceutical sector in the year 2012, Sigma Pharmaceuticals retained its No 3 rank slot... Read more

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X